KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Regeneron Pharmaceuticals (REGN) Cash & Equivalents (2016 - 2025)

Historic Cash & Equivalents for Regeneron Pharmaceuticals (REGN) over the last 17 years, with Q4 2025 value amounting to $3.1 billion.

  • Regeneron Pharmaceuticals' Cash & Equivalents rose 2531.55% to $3.1 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $3.1 billion, marking a year-over-year increase of 2531.55%. This contributed to the annual value of $3.1 billion for FY2025, which is 2531.55% up from last year.
  • Latest data reveals that Regeneron Pharmaceuticals reported Cash & Equivalents of $3.1 billion as of Q4 2025, which was up 2531.55% from $2.5 billion recorded in Q3 2025.
  • In the past 5 years, Regeneron Pharmaceuticals' Cash & Equivalents ranged from a high of $3.9 billion in Q1 2023 and a low of $1.4 billion during Q1 2021
  • Its 5-year average for Cash & Equivalents is $2.7 billion, with a median of $2.7 billion in 2023.
  • In the last 5 years, Regeneron Pharmaceuticals' Cash & Equivalents soared by 13267.96% in 2022 and then plummeted by 4294.13% in 2023.
  • Over the past 5 years, Regeneron Pharmaceuticals' Cash & Equivalents (Quarter) stood at $2.9 billion in 2021, then increased by 7.63% to $3.1 billion in 2022, then decreased by 12.1% to $2.7 billion in 2023, then dropped by 8.86% to $2.5 billion in 2024, then rose by 25.32% to $3.1 billion in 2025.
  • Its Cash & Equivalents was $3.1 billion in Q4 2025, compared to $2.5 billion in Q3 2025 and $2.0 billion in Q2 2025.